Best Hospitals for Balloon Mitral Valvuloplasty in Bengaluru, India

Mitral stenosis (MS) is a valvular heart disease characterized by progressive thickening, calcification, and fusion of the mitral valve leaflet commissures, reducing the normal mitral valve area (MVA) from approximately 4–6 cm² to below 1.5 cm² in hemodynamically significant disease. This obstruction elevates left atrial pressure, causing pulmonary venous hypertension, dyspnea on exertion, atrial fibrillation, hemoptysis, and — in advanced cases — right heart failure and pulmonary arterial hypertension. The dominant etiology worldwide remains rheumatic heart disease, making mitral stenosis disproportionately prevalent in South Asia, the Middle East, Africa, and Latin America — populations that constitute a significant portion of GAF Healthcare's international patient base.

• ELIGIBLE PATIENTS (Indications for BMV):
• Symptomatic mitral stenosis (NYHA Class II–IV) with mitral valve area (MVA) ≤1.5 cm² and favorable valve morphology (Wilkins Score ≤8)
• Asymptomatic severe mitral stenosis (MVA ≤1.0 cm²) with evidence of pulmonary hypertension (PASP >50 mmHg at rest) or new-onset atrial fibrillation
• Patients in whom surgical risk is prohibitively high due to comorbidities (e.g., advanced COPD, severe pulmonary hypertension, elderly patients)
• Pregnant patients with severe, symptomatic mitral stenosis refractory to medical therapy (BMV is the preferred intervention given avoidance of cardiopulmonary bypass and its associated fetal risks)
• +18 more

STANDARD TECHNIQUE — INOUE BALLOON TECHNIQUE: The Inoue technique is the global gold standard for BMV, accounting for the overwhelming majority of procedures performed worldwide. Under fluoroscopic and echocardiographic guidance, the interventional cardiologist gains femoral venous access and advances a catheter to the right atrium. Transseptal puncture using a Brockenbrough needle and Mullins sheath is performed under biplane fluoroscopy and/or intracardiac or transesophageal echocardiographic guidance to cross the interatrial septum safely at the fossa ovalis. The Inoue balloon — a unique self-positioning, pressure-extensible latex balloon with three distinct diameter stages (distal, equatorial, proximal) — is advanced across the mitral valve. Sequential inflation begins with the distal portion anchoring the balloon in the subvalvular apparatus, followed by full inflation at the mitral annulus level, delivering a precisely controlled commissurotomy. The target balloon diameter is calculated using the formula: balloon diameter (mm) = patient height (cm) / 10 + 10, with stepwise dilation under careful hemodynamic and echocardiographic monitoring. Procedural success is defined as an MVA ≥1.5 cm² with MR no greater than grade 2+/4+.

ADVANCED TECHNIQUE — REAL-TIME 3D TRANSESOPHAGEAL ECHOCARDIOGRAPHY (RT-3D TEE) GUIDANCE: Leading centers in India (Mumbai, Chennai, Delhi) and the UAE (Dubai, Abu Dhabi) now perform BMV under real-time 3D TEE guidance, which provides superior visualization of the transseptal puncture site, balloon positioning relative to commissures, and immediate post-dilation assessment of commissural splitting and MR grade. This approach significantly reduces fluoroscopy time and radiation exposure, and is particularly valuable in patients with complex anatomy, prior commissurotomy, or pregnancy.

ADVANCED TECHNIQUE — INTRACARDIAC ECHOCARDIOGRAPHY (ICE)-GUIDED BMV: ICE-guided BMV eliminates the need for general anesthesia (which is otherwise required for TEE guidance), allowing the procedure to be performed under conscious sedation alone. An ICE catheter (typically 8 Fr, 64-element phased array) is positioned in the right atrium to guide transseptal puncture and monitor balloon positioning. This approach is increasingly adopted in high-volume centers and is associated with shorter procedure times and improved patient comfort.

DOUBLE-BALLOON TECHNIQUE: The double-balloon technique (using two separate balloon catheters advanced across the mitral valve) was the predecessor to the Inoue technique. It is now largely superseded by the Inoue balloon but may be used in specific anatomical scenarios where larger effective balloon dilating areas are required.

PHASE 1 — REMOTE EVALUATION (2–4 weeks before travel):

The patient's journey begins with GAF Healthcare's remote medical review. The patient submits recent echocardiography reports, ECG, chest X-ray, blood work, and clinical history through GAF Healthcare's secure digital platform. A GAF-affiliated interventional cardiologist reviews the data, calculates the Wilkins Score, assesses MVA, and determines BMV candidacy. A personalized treatment plan, cost estimate, and hospital recommendation are issued within 48–72 hours.

PHASE 2 — ARRIVAL AND PRE-PROCEDURAL WORKUP (Day 1–2):